Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2003

View Archived Issues

NN-703 may be effective in adults with moderately severe GH deficiency

Antiviral and spermicidal agent WHI-05 in development

NXC-4720 generates positive data in validation studies

Improved vision in extension phase of Lucentis wet AMD study

Development of AS-1403 discontinued following phase I biodistribution results

Findings from DAC:GLP-1 studies reported

Vical and Merck & Co. amend license agreement

Medtronic to commercialize rhBMP-2 in Japan

Novel telomerase inhibitors covered by Cancer Research Technology patent

New mGluR5 antagonists in early development at Merck

Boehringer Igelheim describes new glucocorticoid receptor modulators and their use

Novel pyridazinone-based p38 kinase inhibitors prepared by Pharmacia researchers

Bayer scientists prepare and test new gamma-secretase inhibitors for AD therapy

DakoCytomation and Northwest Biotherapeutics to develop prostate cancer diagnostics

Zengen drug delivery technology used for oral strip products

Meditech and Elan extend joint venture

Phase II Campath trial in MS makes progress

TZE-5323: a potential therapeutic drug for the long-term treatment of endometriosis

Synthetic progestins with high tissue and receptor selectivity

PHA-927F reported to be a potent and selective inhibitor of tissue factor/factor VIIa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...